UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 82 filers reported holding UROGEN PHARMA LTD in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $649,980 | +40.4% | 46,394 | +3.7% | 0.00% | – |
| Q2 2023 | $462,893 | +24.4% | 44,724 | +4.8% | 0.00% | – |
| Q1 2022 | $372,000 | -8.4% | 42,689 | 0.0% | 0.00% | – |
| Q4 2021 | $406,000 | -43.5% | 42,689 | 0.0% | 0.00% | – |
| Q3 2021 | $719,000 | +16.2% | 42,689 | +5.4% | 0.00% | – |
| Q2 2021 | $619,000 | -22.2% | 40,515 | -0.8% | 0.00% | – |
| Q1 2021 | $796,000 | +7.6% | 40,853 | -0.4% | 0.00% | – |
| Q4 2020 | $740,000 | -4.1% | 41,036 | +2.7% | 0.00% | – |
| Q3 2020 | $772,000 | -29.3% | 39,970 | -4.4% | 0.00% | -100.0% |
| Q2 2020 | $1,092,000 | +50.8% | 41,796 | +3.0% | 0.00% | – |
| Q1 2020 | $724,000 | -46.3% | 40,564 | +0.5% | 0.00% | -100.0% |
| Q4 2019 | $1,347,000 | +44.2% | 40,354 | +3.0% | 0.00% | 0.0% |
| Q3 2019 | $934,000 | -33.3% | 39,185 | +0.5% | 0.00% | 0.0% |
| Q2 2019 | $1,401,000 | – | 38,977 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |